Immune cells from your own tumor could fight advanced melanoma

NCT ID NCT06703398

Recruiting now Disease control Sponsor: Shanghai Juncell Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 06, 2026 · Updated 2 times

Summary

This Phase 2 trial tests a new treatment called GC101 TIL for people with advanced melanoma that has not responded to standard therapies. The treatment uses immune cells taken from the patient's own tumor, grown in a lab, and then given back to fight the cancer. About 98 participants will be randomly assigned to receive either GC101 TIL or standard chemotherapy. The study aims to see if the TIL therapy can slow cancer growth and improve survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GC101 TIL (tumor-infiltrating lymphocytes)
What this could lead to: If successful, this could offer a new treatment option for advanced melanoma patients who have not responded to standard therapies.
What could go wrong: This is a Phase 2 trial with only 98 participants, so results may not be definitive. TIL therapy can cause serious side effects like immune reactions and infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma metastatic melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MELANOMA

Contacts and locations

Locations

Beijing Cancer Hospital
RECRUITING

Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.